We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Nifurtimox

News List

FDA Approves Lampit for Chagas Disease in Pediatric Patients americanpharmaceuticalreview
August 25, 2020
The U.S. Food and Drug Administration (FDA) approved Lampit (nifurtimox) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg).
Bayer's Ph III clinical trial of Nifurtimox in pediatric patients with Chagas Disease meets primary endpoint biospectrumasia
March 18, 2019
Chagas is an infectious disease caused by a parasite (Trypanosoma cruzi) and transmitted to humans via the feces of triatomines, also known as kissing bugs.
Bayer's Ph III clinical trial of Nifurtimox in pediatric patients with Chagas Disease meets primary endpoint biospectrumasia
March 15, 2019
Chagas is an infectious disease caused by a parasite (Trypanosoma cruzi) and transmitted to humans via the feces of triatomines, also known as kissing bugs.